Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release

Peter Teismann, B Ferger

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


In vivo microdialysis with the new antidementia compound ensaculin was performed in freely moving rats to study the alterations in dopaminergic and glutamatergic neurotransmission. Ensaculin (0.1 and 1 mg/kg i.p.) significantly increased extracellular levels of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Furthermore, ensaculin (1 mg/kg i.p.) showed a non-significant tendency to reduce the K(+)-induced glutamate release. The data suggest that ensaculin may have moderate D(2) antagonistic properties. Thus, besides its possible role as a cognitive enhancer, ensaculin may also have moderate antipsychotic properties.
Original languageEnglish
Pages (from-to)247-250
Number of pages4
JournalEuropean Journal of Pharmacology
Issue number2
Early online date13 Jun 2000
Publication statusPublished - 16 Jun 2000


  • 3,4-Dihydroxyphenylacetic Acid
  • Animals
  • Benzopyrans
  • Chromatography, High Pressure Liquid
  • Corpus Striatum
  • Dopamine
  • Glutamic Acid
  • Homovanillic Acid
  • Male
  • Microdialysis
  • Piperazines
  • Potassium
  • Rats
  • Rats, Wistar
  • Ensaculin
  • Dopamine
  • DOPAC (3,4-dihydroxyphenylacetic acid)
  • Glutamate
  • Rat


Dive into the research topics of 'Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release'. Together they form a unique fingerprint.

Cite this